Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

Launched by ST. JUDE CHILDREN'S RESEARCH HOSPITAL · Dec 1, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of a special dye called Indocyanine Green (ICG) to help surgeons locate important lymph nodes in children with certain types of solid tumors, such as Wilms tumor or para-testicular rhabdomyosarcoma. The goal is to see how well this dye works in guiding the surgeon during a procedure called retroperitoneal lymph node dissection, which is done to check if cancer has spread. The researchers also want to ensure that using ICG is safe and to find out if any serious side effects occur.

To be eligible for this study, participants must be under 21 years old and have a solid tumor that requires surgery. However, those with a history of allergies to iodine, pregnant females, or those who have had extensive prior surgeries that could affect how the lymph nodes work will not be included. If a child participates, they can expect to receive the ICG dye before their surgery, and the doctors will carefully monitor them for any side effects. This trial is currently looking for more participants, and the findings could help improve surgical outcomes for young patients with these tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient under the age of 21 years with visceral pediatric solid tumor suspected to be Wilms tumor or para-testicular rhabdomyosarcoma requiring retroperitoneal lymph node dissection.
• Exclusion Criteria:
• • Subjects with a history of iodide allergies.
• • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
• • Pregnant female.
• • Patients with extensive prior surgery at the primary site or nodal basin expected to affect the lymphatic drainage.

Trial Officials